Twist Bioscience Corp shares slipped 7.1% in pre-open trading after the company released its fiscal fourth-quarter 2026 results prior to the opening bell. The key driver of the move was an earnings-per-share figure that was meaningfully wider than Wall Street had expected.
Analysts had modeled a loss of roughly $0.38 per share and anticipated revenue near $123.6 million, a year-over-year gain of about 25%. While the company did top revenue expectations modestly, the reported EPS was roughly 16.7% worse than consensus, amplifying investor disappointment.
Market participants noted that the earnings miss mattered more than it might have for a lower-valued company because Twist entered the report with valuation metrics that implied elevated expectations. The company's price-to-sales ratio was trading well above both its historical median and common industry multiples, meaning any shortfall on profitability measures was likely to be penalized by investors.
Sentiment around the stock had already been fragile. A bearish piece published the prior week by The Bear Cave, a publication owned by Hunterbrook Media, argued that Twist carries a valuation premium no peer commands and suggested the recent rally may have outpaced the underlying business. That report, combined with short interest near 16% and roughly $146.7 million in insider selling over the trailing twelve months, left the name exposed to downside pressure.
The broader market provided little support. The NASDAQ declined 0.9% and the S&P 500 slipped 0.4% in the session referenced in the company's report, creating a headwind that generally hurts high-beta growth stocks. Twist’s beta is approximately 2.25, a sensitivity that tends to magnify market moves for investors in the stock. The life-science tools and genomics sector more generally has come under scrutiny about whether AI-led demand narratives will convert into near-term earnings, and peers such as Illumina have also experienced selling pressure in recent weeks.
Putting the elements together, the combination of a profitability miss inside a premium valuation, lingering fallout from the short-seller write-up, high short interest and substantial insider dispositions, all against a risk-off market backdrop, pushed Twist shares sharply lower in pre-market trading. The decline erased a sizable portion of the gains the stock had accumulated in recent months.
Sectors affected - The story touches directly on the genomics and life-science tools sector, and more broadly on high-beta growth equities within the technology and biotech segments, as well as the broader market indices that serve as a backdrop for such names.